{
    "clinical_study": {
        "@rank": "21653", 
        "acronym": "EuroHYP-1", 
        "arm_group": [
            {
                "arm_group_label": "Hypothermia", 
                "arm_group_type": "Experimental", 
                "description": "Best medical treatment + hypothermia 34-35\u00b0C for 24h"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "Best medical treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if systemic cooling to a target temperature of 34\n      to 35\u00b0C, started within 6 hours of symptom onset and maintained for 24 hours, improves\n      functional outcome at 3 months in patients with acute ischaemic stroke."
        }, 
        "brief_title": "Cooling Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischaemic Stroke", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent obtained from the patient or his/her legally acceptable\n             representative or under such other arrangements as may be legally established in\n             participating countries\n\n          -  Patients of both sexes aged \u226518 years\n\n          -  Estimated body weight of 50 up to and including 120kg\n\n          -  Diagnosis of acute ischaemic stroke\n\n          -  Possibility to start therapeutic hypothermia within 6 hours after onset of stroke\n\n          -  Possibility to start therapeutic hypothermia within 90 minutes after start of\n             alteplase administration in patients receiving thrombolysis\n\n          -  Possibility to start therapeutic hypothermia within 90 minutes after admission to\n             trial site in patients not receiving thrombolysis\n\n          -  mRS score \u22642 prior to onset of stroke\n\n          -  NIHSS score of 6 up to and including 18\n\n          -  GCS motor response subscale score \u22655\n\n        Exclusion Criteria:\n\n          -  Use of monoamineoxidase inhibitors in the 14 days prior to screening\n\n          -  Current use of medication interacting with pethidine or buspirone, i.e., ritonavir,\n             phenytoin, cimetidine, phenothiazines, opioids and partial opioid agonists (e.g.,\n             pentazocine, nalbuphine, buprenorphine)\n\n          -  Acute alcohol intoxication\n\n          -  Opioid addiction\n\n          -  Nursing mother or pregnant woman, as verified by a positive urine pregnancy test in\n             females of childbearing potential\n\n          -  Known hypersensitivity to the IMPs or any of their formulation ingredients\n\n          -  Patient who is imprisoned or is lawfully kept in an institution\n\n          -  Employee or direct relative of an employee of the CRO (if applicable), the department\n             of the investigator, or the sponsor\n\n          -  Participation in an interventional clinical trial within the last 4 weeks, or be\n             under the exclusion period from another trial\n\n          -  Prior participation in this trial\n\n          -  Any acutely life-threatening conditions other than acute ischaemic stroke\n\n          -  Rapidly resolving stroke symptoms\n\n          -  Evidence from CT or MRI of intracranial haemorrhage or tumour or encephalitis or any\n             diagnosis likely to cause the present symptoms other than acute ischaemic stroke.\n             Haemorrhagic transformation of the infarct is not an exclusion criterion, except when\n             there is a parenchymal haematoma covering more than 30% of the infarcted area, with\n             significant space-occupying effect, or when there is a bleeding remote from the\n             infarcted area\n\n          -  Known convulsive disorder, acute closed angle glaucoma, myasthenia gravis\n\n          -  SPO2 <94% (as measured by pulse oximetry) under nasal oxygen administration\n\n          -  Other severe respiratory disorder\n\n          -  Bradycardia (<40 bpm)\n\n          -  Severe cardiac failure, defined as NYHA classification \u2265III\n\n          -  Myocardial infarction or angina pectoris in the 3 months prior to screening\n\n          -  Vasospastic disorders (e.g., Raynaud's disease)\n\n          -  Haematological dyscrasia (e.g., sickle cell disease, cryoglobulinaemia)\n\n          -  Known platelet count <100,000/mm3\n\n          -  Known INR >1.7\n\n          -  Skin damage (e.g., inflammation, burns, injuries, ulcerations, hives, rash) at the\n             sites intended to be used for cooling\n\n          -  Clinical diagnosis of sepsis\n\n          -  Known severe hepatic impairment (serum ALAT and/or ASAT >3 times ULN)\n\n          -  Known renal impairment (serum creatinine >2mg/100ml)\n\n          -  Addison's disease\n\n          -  Any other condition that may interfere with, or be aggravated by, therapeutic\n             hypothermia\n\n          -  Any condition that is thought to reduce the compliance to cooperate with the trial\n             procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01833312", 
            "org_study_id": "EuroHYP-1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Hypothermia", 
                "description": "In patients randomised to therapeutic hypothermia, induction of cooling will be started by infusion of 4\u00b0C isotone saline or Ringer's lactate administered over a period of 30 to 60 minutes. A body temperature between 34.0 and 35.0\u00b0C will be targeted. Body temperature will be monitored through bladder or rectal thermal probes, and cooling procedures will be adapted to keep body temperature as close as possible to the target. Maintenance of body temperature in the target range will be performed with a surface or endovascular cooling device. After a cooling period of 24h, controlled rewarming to 36\u00b0C with a rate of 0.2\u00b0C/h will be started. After 36\u00b0C have been reached, the device will be disconnected.", 
                "intervention_name": "Hypothermia", 
                "intervention_type": "Device", 
                "other_name": [
                    "EMCOOLS Brain.Pad", 
                    "Arctic Sun and ArcticGel Pads", 
                    "CritiCool and CureWrap 3500", 
                    "Zoll intravascular temperature management system"
                ]
            }, 
            {
                "arm_group_label": "Hypothermia", 
                "description": "anti-shivering treatment", 
                "intervention_name": "Buspirone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Hypothermia", 
                "description": "anti-shivering treatment", 
                "intervention_name": "Pethidine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Buspirone", 
                "Meperidine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "acute ischemic stroke", 
            "hypothermia"
        ], 
        "lastchanged_date": "July 31, 2013", 
        "location": {
            "contact": {
                "email": "dimitre.staykov@uk-erlangen.de", 
                "last_name": "Dimitre Staykov, PD Dr.", 
                "phone": "+4991318533001"
            }, 
            "facility": {
                "address": {
                    "city": "Erlangen", 
                    "country": "Germany", 
                    "zip": "91054"
                }, 
                "name": "Department of Neurology, University Hospital Erlangen"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "EuroHYP-1: European Multicentre, Randomised, Phase III Clinical Trial of Therapeutic Hypothermia Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischaemic Stroke", 
        "other_outcome": [
            {
                "description": "MMPs including gelatinases (MMP-2 and MMP-9), collagenases (MMP-1, MMP-8 and MMP-13) and stromelysins (MMP-3 and MMP-10) using multiplex ELISA [SearchLight technology].\nMMP endogen inhibitors (TIMP-1 and TIMP-2) using multiplex ELISA [SearchLight technology].\nH-FABP, UFD-1, RNABP, NDKA, GSTP-1 and Pro-BNP using standard ELISA.\nCerebral Array I & II containing BDNF, GFAP, NSE, NGAL, sTNFRI, D-dimer and CRP using biochip analysers [Randox].\nPro-ANP, Copeptin, IL6, IL8, IL10, mannose-binding lectin (MBL), mHLA-DR, monocytotic cytokine-secretion ex vivo stimulation, C5a in plasma, ultrasensitive PCT, lipopolysaccharide-binding protein (LBP).", 
                "measure": "Selected biomarkers", 
                "safety_issue": "No", 
                "time_frame": "baseline, 24h, 72h"
            }, 
            {
                "description": "Presence, location and extent of any visible infarct, early infarct swelling, hyperdense artery, leukoaraiosis, atrophy and prior infarct on the scan performed at screening assessment (within 90 minutes before the start of the treatment) will be tested for any interaction with early (infarct swelling, haemorrhagic transformation, neurological deterioration, death) and late (NIHSS and mRS scores, death) neurological and functional outcome variables at day 8 or day of discharge from hospital, whichever occurs firs, and at outcome assessment (day 91\u00b114).", 
                "measure": "Other imaging parameters", 
                "safety_issue": "No", 
                "time_frame": "baseline, 48h"
            }, 
            {
                "description": "Patient location during stay in hospital.\nDestination after discharge from hospital.", 
                "measure": "Cost-effectiveness parameters", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "overall_contact": {
            "email": "direktion-neurologie@uk-erlangen.de", 
            "last_name": "Stefan Schwab, Prof. Dr.", 
            "phone": "+49-9131-8534563"
        }, 
        "overall_contact_backup": {
            "email": "dimitre.staykov@uk-erlangen.de", 
            "last_name": "Dimitre Staykov, Priv.Doz Dr", 
            "phone": "+49-9131-8544539"
        }, 
        "overall_official": {
            "affiliation": "University of Erlangen-Nuremberg", 
            "last_name": "Stefan Schwab, Prof", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Analysed with ordinal logistic regression and expressed as a common odds ratio.", 
            "measure": "modified Rankin scale", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01833312"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "NIHSS;\nWorld Health Organization Disability Assessment Schedule (WHODAS) 2.0", 
                "measure": "Neurological outcome", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "EuroQoL 5-dimensions 5-level questionnaire", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Evaluated on CT or MRI imaging", 
                "measure": "Cerebral infarct size", 
                "safety_issue": "No", 
                "time_frame": "48\u00b124 hours"
            }, 
            {
                "description": "Number of adverse events and severe adverse events related to the procedure of systemic cooling including induction, maintenance of hypothermia, rewarming, or the administration of anti-shivering medication (pethidine and buspirone) within the first 36h of enrollment.\nNumber of adverse events and severe adverse events until outcome assessment at day 91.", 
                "measure": "Safety of systemic cooling", 
                "safety_issue": "Yes", 
                "time_frame": "Enrollment - day 91"
            }, 
            {
                "description": "Timing and dose of anti-shivering medication.\nBedside shivering assessment scale (BSAS).", 
                "measure": "Tolerability of systemic cooling", 
                "safety_issue": "No", 
                "time_frame": "36 hours"
            }
        ], 
        "source": "University of Erlangen-N\u00fcrnberg Medical School", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Erlangen-N\u00fcrnberg Medical School", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}